Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control

Observational Study on Efficacy on Glycaemic Control of Slow-acting Insulin Analogue in Type 2 Diabetes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00700960

Acronym

LIGHT

Enrollment

2745

Registered

2008-06-19

Start date

2007-06-30

Completion date

2008-11-30

Last updated

2017-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Europe. The aim of this observational study is to describe the conditions for the concomitant administration of a slow-acting insulin analogue with oral antidiabetics (OADs) in order to improve blood glucose control in type 2 diabetes.

Interventions

DRUGinsulin detemir

initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * HbA1c level greater than 7% despite treatment with two (or three) oral antidiabetic drugs (OADs) at an optimal dose level * Patient agreeing to take part in the study and capable of completing a self-questionnaire.

Exclusion criteria

* Hypersensitivity to insulin or to one of the excipients * Treatment with insulin for at least 6 months * Participant in a clinical trial for diabetes on entry into the observational study

Design outcomes

Primary

Measure	Time frame
HbA1c	After 3 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026